Fierce Biotech1d
Eisai's abandoned Enhertu challenger set to live on at BlissBio
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
Pharmabiz2d
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...
BioPharma Dive4d
Taiho buys Swiss biotech and its ADC tech for $400M
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...
Fierce Pharma4d
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...